Curium invests €32M in France to make targeted prostate cancer therapy
What's the deal? CuriumDealroom has a profile for this one. Try Dealroom →, a global nuclear medicine company, will invest more than €32 million to build a European production line for ¹⁷⁷Lu-PSMA-I&T at its Saclay site in France. The therapy targets patients with metastatic castration-resistant prostate cancer, and the project will create 20 highly skilled jobs.
Why now? Curium announced the plan at the Choose France summit in Versailles, part of a broader push to secure France's place in the European nuclear medicine value chain. The company has invested more than €50 million in France between 2021 and 2026.
What's the endgame? The move positions Curium as a theranostic player, pairing its diagnostics expertise with a growing therapeutic portfolio built around radioligand therapy (RLT). RLT combines a molecular vector that targets tumour cells with a radioactive isotope, delivering treatment directly to the tumour while sparing healthy tissue.
Curium already employs over 750 people in France across 13 production sites serving more than 200 nuclear medicine centres daily. France accounts for more than 20% of its global revenue.
The signal: Nuclear medicine is shifting from diagnosis toward targeted treatment, and demand is set to climb sharply. In France, the number of patients eligible for RLT could rise more than tenfold by 2035.
"Radioligand therapy in particular, is set to become an essential component of the modern therapeutic arsenal against cancer," said Ciril Faia, Curium International's chief executive officer.
Read more: beixinews.com
Image credit: Generated with Gemini
